<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00841568</url>
  </required_header>
  <id_info>
    <org_study_id>156-05-002</org_study_id>
    <secondary_id>JapicCTI-090690</secondary_id>
    <nct_id>NCT00841568</nct_id>
  </id_info>
  <brief_title>A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]</brief_title>
  <official_title>A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation into the long-term safety and efficacy of OPC-41061 in repeated oral
      administrations at doses of 15 mg twice daily in patients with ADPKD who completed the
      preceding dose-finding study (156-04-001).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigation into the long-term safety and efficacy of OPC-41061 in repeated oral
      administrations at doses of 15 mg twice daily in patients with ADPKD who completed the
      preceding dose-finding study (156-04-001).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: adverse events, laboratory values, plasma AVP concentration, vital signs, body weight, and ECG</measure>
    <time_frame>156 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: combined renal volume (right and left kidneys) and renal function test</measure>
    <time_frame>156 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacology: urine osmolality</measure>
    <time_frame>156 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Autosomal Dominant Polycystic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-41061</intervention_name>
    <description>orally administered at 15 mg twice daily (morning and evening) for a maximum of 3 years.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who completed 5-day repeated administrations and the follow-up observation in
             the preceding study (156-04-001)

          -  Patients in whom the safety of repeated administration was confirmed based on the
             investigator's reports from the preceding study (156-04-001)

        Exclusion Criteria:

          -  Patients with serum creatinine concentration of 2.5 mg/dL or higher at the screening
             examination

          -  Patients with any of the following complications

               -  Uncontrolled hypertension

               -  Serious cardiovascular disease (eg. heart failure) or hepatic disease (eg.
                  cirrhosis)&quot;

          -  Patients with any of the following complications or history thereof

               -  Clinically significant drug allergies (anaphylaxis) or hypersensitivity
                  (especially, hypersensitivity to benzazepine derivatives or suspected
                  hypersensitivity thereto)

               -  Inability to personally give consent due to a mental disease &quot;

          -  Patients with SBP (in sitting position) &lt;90 mm Hg (at screening examination)

          -  Patients with history of massive bleeding or bleeding tendency

          -  Patients with a history of drug or alcohol abuse within 6 months prior to the
             screening examination

          -  Pregnant women, lactating women, or women who may become or plan to become pregnant

          -  Patients who received any investigational drug other than OPC-41061 within 30 days
             prior to commencement of administration of OPC-41061

          -  Any patient who, in the opinion of the principle investigator or attending
             investigators, should not participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Kanto Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2009</study_first_submitted>
  <study_first_submitted_qc>February 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2009</study_first_posted>
  <last_update_submitted>April 7, 2011</last_update_submitted>
  <last_update_submitted_qc>April 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Kyoji Imaoka, Operating Officer, Director</name_title>
    <organization>Department of Clinical Research and Development, Otsuka Pharmaceutical Co., Ltd.</organization>
  </responsible_party>
  <keyword>ADPKD</keyword>
  <keyword>Tolvaptan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 17, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

